today show semaglutide GLP-1 meds might be getting more affordable, but is that really solving the main issue? , #glp1 #insurancecoverednutritioncounseling #healthyrelationshipwithfood #nycnutritionist #foodfreedom Weight-Loss Pill Study Compares Effectiveness

These two drugs, developed by Danish pharmaceutical company Novo Nordisk, have been making waves in chronic weight management

GIP(3-30)NH 2 demonstrated an inhibition of the GIP-potentiated glucose-stimulated insulin secretion by 82%

Therapeutic approaches for sarcopenia in T2D The therapeutic approaches, including antidiabetic medications and anabolic agents, offer promising strategies for managing sarcopenia in T2D by improving muscle health, metabolic function, and overall well-being [114]

In T2D participants, increases in 3-HB and the C2/C0 ratio were much smaller, although reductions in BCAAs were comparable to those observed in the obesity cohort

It suppresses their appetite, so they forget to eat

You can read the full article at Tirzepatide (TZP), a new dual GIP/GLP-1 receptor agonist for treating type 2 diabetes (T2D), displayed superior outcomes in HbA1c reduction and patients achieving target levels compared to semaglutide and titrated insulin degludec across 40-weeks (SURPASS-2) and 52-weeks (SURPASS-3) studies